Psychiatric Annals

Review Article 

Cariprazine: Pharmacology and Use in the Clinical Management of Psychiatric Disorders

Ayman Antoun Reyad, PhD, PGCert; Raafat Mishriky, MBBCH, PgDip, MRCPsych

Abstract

Cariprazine is a new atypical antipsychotic for management of schizophrenia and bipolar disorder. This article examines the role of cariprazine, a partial D2 and D3 receptor agonist (with a higher affinity for the D3 receptor), in the management of psychiatric conditions. Cariprazine leads to significant improvements in scores on psychiatric scales such as the Positive and Negative Syndrome scale, the Clinical Global Impressions scale, and the Young Mania Rating scale, but it is also associated with side effects such as akathisia, restlessness, and insomnia. These findings can help guide psychiatrists and pharmacists in their clinical role of supporting their psychiatric patients. [Psychiatr Ann. 2019;49(3):129–134.]

Abstract

Cariprazine is a new atypical antipsychotic for management of schizophrenia and bipolar disorder. This article examines the role of cariprazine, a partial D2 and D3 receptor agonist (with a higher affinity for the D3 receptor), in the management of psychiatric conditions. Cariprazine leads to significant improvements in scores on psychiatric scales such as the Positive and Negative Syndrome scale, the Clinical Global Impressions scale, and the Young Mania Rating scale, but it is also associated with side effects such as akathisia, restlessness, and insomnia. These findings can help guide psychiatrists and pharmacists in their clinical role of supporting their psychiatric patients. [Psychiatr Ann. 2019;49(3):129–134.]

Schizophrenia and bipolar disorder are severe psychiatric conditions in which a person's perception, thoughts, moods, and behavior are changed from normal.1,2 Schizophrenia affects 21 million people worldwide and is a leading cause of disability.3 A diagnosis of schizophrenia is confirmed by a psychiatrist after full assessment using criteria from The International Statistical Classification of Diseases and Related Health Problems, 10th edition,4 or the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.5 Schizophrenia symptoms can be divided into two groups: positive (such as hallucinations and delusions) and negative (which affect the patients' ability to function, such as a lack of motivation).6 These symptoms need to be present for a least 1 month before the diagnosis is made. The etiology of schizophrenia is not fully understood; however, genetic and environmental factors, including stress, traumatic life experiences, and cannabis use could be involved.7 About 80% of patients with schizophrenia have a relapse within 5 years of recovery;8 this risk is decreased by using maintenance antipsychotic medications.9 Antipsychotics provide relief from these debilitating symptoms and have been used successfully in the treatment of bipolar disorders.10

First-generation antipsychotics such as haloperidol and chlorpromazine are dopamine (D2) receptor antagonists and can block histamine, muscarinic, and alpha-1 receptors.11 Second-generation antipsychotics (SGA) are serotonin-dopamine antagonists.12 Antagonism of the serotonin 2A receptor (5-HT2A) can increase dopaminergic neurotransmission in the nigrostriatal pathway with less risk of extrapyramidal symptoms (EPS).13 SGA's main side effects are weight gain, glucose intolerance, and hyperprolactinemia.14,15

In this review we describe cariprazine, a new atypical antipsychotic drug for the management of schizophrenia and bipolar disorder.16 Cariprazine acts as a D2 and D3 receptor partial agonist with a higher affinity for the D3 receptor,17 which differs from current antipsychotics.10 Cariprazine metabolism occurs via the cytochrome P450 (CYP)3A4 and CYP2D6 pathways. There are two clinically relevant metabolites, desmethyl-cariprazine and didesmethyl-cariprazine, that have similar pharmacological activity to cariprazine, but didesmethyl-cariprazine has a much longer half-life (1–3 weeks) compared to cariprazine (2–4 days).18,19 Common side effects of cariprazine include restlessness, akathisia, and insomnia.17,18

Pharmacology of Cariprazine

Schizophrenia is associated with multifactorial dysfunctions in glutamatergic, dopaminergic, and gamma-aminobutyric acid (GABA)-ergic neurotransmission in the central nervous system. Serotonin (5-HT) also plays a crucial role in regulating psycho-emotional, cognitive, and motor functions.20,21 Cariprazine could influence acute changes in glutamate, dopamine, noradrenaline, and serotonin levels in a dose-dependent manner.21 Cariprazine binds dopamine D2 and D3 receptors in a dose-dependent/saturable manner,22 acting as a partial agonist of the D2 receptor similar to aripiprazole,23 with a 10-fold higher affinity for the D3 receptor compared to the D2 receptor (pKi of 10 and 9, respectively). Cariprazine has high affinity to 5-HT2B receptor as an antagonist, moderate affinity to the 5-HT1A receptor as a partial agonist, and low affinity to the 5-HT2A receptor as an antagonist.24 Moreover, cariprazine displays moderate/low affinity for the histamine (H1) and 5-HT2C receptors.25,26 Activation of D2 modulates G-protein/cyclic AMP-dependent signaling and Akt-GSK-3 signaling with effects on behaviors (such as the activity of lithium for management of mania). In a study from 2015, cariprazine was more potent than aripiprazole as an antagonist in inhibiting isoproterenol-induced cyclic AMP and in D2R/beta-arrestin 2-dependent interactions.27 Cariprazine upregulated the D2, D3, and 5-HT1A receptor levels and decreased N-methyl-D-aspartate receptor levels in several brain regions.28 Dopamine receptors differ in signal transduction, binding profile, localization, and physiological effects, with the D3 receptor involved in schizophrenia, Parkinson's disease, addiction, anxiety, and depression.29

Pharmacokinetics of Cariprazine

Cariprazine has good blood-brain barrier penetration with slow washout.30 Oral bioavailability is 52% with a brain to plasma area-under-the-curve ratio of 7.6:1.31 Cariprazine is mainly metabolized hepatically by CYP3A4.32 The CYP2D6-mediated pathway plays a minor role in cariprazine metabolism, with CYP2D6 inhibitors unlikely to have clinically relevant effects.33 It has two equipotent metabolites: desmethyl and didesmethyl cariprazine.34 Cariprazine and its active didesmethyl derivative are cleared slowly (elimination half-lives range from 2–5 days for cariprazine to 2–3 weeks for didesmethyl-cariprazine),35 and steady state is reached within 1 to 2 weeks.18 Cariprazine is a P-glycoprotein (P-gp) inhibitor in vitro, so the use of P-gp substrates with a narrow therapeutic index such as dabigatran and digoxin requires careful monitoring.33

Cariprazine in the Management of Bipolar Disorder

Bipolar disorder is a chronic disorder characterized by episodic recurrences of mania and depression with periods of remission.36 In animal studies, cariprazine showed similar efficacy to lithium.27 Several human studies showed the efficacy of cariprazine using the Young Mania Rating Scale (YMRS) total score, YMRS single items, and Clinical Global Impressions-Severity of Illness (CGI-S) score. In a clinical trial with 497 patients, cariprazine showed superiority on all 11 YMRS scale single items.37 Rates of remission and global improvement were greater for cariprazine, with no decline or switch to depression.38 Another trial confirmed cariprazine's superiority in reducing YMRS and CGI-S scores, with a significant percentage of patients achieving remission.39

Cariprazine in the Management of Schizophrenia

Compounds with combined 5-HT1A/D2 activities could be effective in managing a broader range of schizophrenia symptoms,40 as 5-HT1A activation leads to improved negative/cognitive symptoms with reduction of EPS induced by D2 antagonism.21,41 Cariprazine significantly attenuated disrupted social recognition, attention, and memory in a study by Zimnisky et al.,42 and caused reversal of novel object recognition impairment in a study by Watson et al.43

Cariprazine is efficacious in controlling schizophrenia symptoms, as patients have a significantly longer time to relapse.44 Cariprazine was shown to reverse cognition and social behavior deficits in rats,45 and in humans it showed better efficacy compared to risperidone46 and was superior to many antipsychotics, including aripiprazole.47

Randomized controlled trials have shown significant efficacy of cariprazine on the Positive and Negative Syndrome Scale (PANSS; on total, positive, and negative scales), with fewer patients discontinuing treatment.48,49 CGI-S score changes at week 6 were significant.50 Patients with predominantly negative symptoms achieved better health states and less anhedonia compared with risperidone, with estimated quality-adjusted life year gain of 0.029 per patient.51,52

Cariprazine in the Management of Other Psychiatric Conditions

Cariprazine could be used as an adjunctive therapy in depression management. In a study by Leggio et al.53 dopamine regulation was associated with the efficacy of some antidepressants, such as desipramine, as dopaminergic dysfunction in the mesolimbic system contributed to anhedonia and psychomotor retardation, whereas D3 receptor expression is down-regulated in depression. Cariprazine attenuated anhedonic-like behavior in mice while reducing drinking latency (anxiolytic-like activity).54 Cariprazine was efficacious in reducing the Montgomery-Åsberg Depression Rating Scale total score.55,56

Cariprazine showed significant efficacy in reducing hostile and aggressive behavior as determined using the PANSS hostility item (P7), especially in patients with greater baseline hostility.57 Cariprazine could prevent relapse in people with cocaine addiction and reduce the cocaine-rewarding effect.58

Cariprazine Tolerability

Cariprazine had low (<10%) rates of sedation and treatment discontinuation (<5%) but high rates of akathisia (33%)59 with fewer EPS compared to risperidone60 (cariprazine 3 mg: 8.9%; risperidone 4 mg: 12.9%) in patients with acute exacerbation of schizophrenia.49 Insomnia, vomiting, and headache were reported in 10% or more of patients, whereas prolactin levels decreased with no significant changes in liver enzymes; mean body weight change was 1.58 kg.61 More cariprazine patients experienced treatment-emergent akathisia (cariprazine: 22%; placebo: 6%) or EPS (cariprazine: 16%; placebo: 1%).37 Cariprazine was associated with akathisia, EPS, and diastolic blood pressure symptoms in a dose-response relationship, with significant fasting glucose level changes (7 mg/dL compared to just 1.7 mg/dL for placebo), whereas no clinical changes in electrocardiogram parameters or high QTc (>500 ms) were observed.19 A multicenter clinical trial showed no unexpected safety issues/deaths.62 Restlessness, nausea, dyspepsia, tremor, and back pain were common (incidence ≥5%).63 Somnolence is uncommon as cariprazine is considered an activating medication (number needed to harm = 65; low somnolence risk).64,65 Cariprazine is similar to haloperidol and aripiprazole in that it affects 7-dehydrocholesterol conversion to cholesterol.66

Conclusion

This review investigated the efficacy and safety of cariprazine for psychiatric conditions management. Cariprazine is taken once daily (1.5–6 mg) and without regard to food. The cariprazine dose should be adjusted in patients who receive CYP450 inhibitors, and it is contraindicated for patients with severe hepatic or renal disease.67 Cariprazine is a D3 and D2 receptor partial agonist with higher selectivity for the D3 receptor, which is expressed mainly in brain areas associated with motivation and reward-related behavior.68

In patients with schizophrenia, cariprazine resulted in significant improvement in PANSS total score and improved negative symptoms compared to other antipsychotics such as risperidone. Patients taking cariprazine showed significant improvements in CGI-S score and many shifted from the extremely/severely ill category to the mildly ill/better category.69 This second-generation antipsychotic with D3 receptor partial agonist properties could also improve cognitive function. In people with bipolar disorder, cariprazine resulted in significant improvements in YMRS and was efficacious as monotherapy, resulting in improved remission rates (odds ratio, 2.08).70 It is recommended alone or in combination as a first-line treatment for acute mania.71 There was significantly higher risk of EPS72 but a lower risk of discontinuing.69 Clinical trial results need to be interpreted with caution as treatment length was short (3–6 weeks) in most of the studies, several different doses were used, and there was no clear evidence for long-term effects.

References

  1. The National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178. Accessed February 13, 2019.
  2. Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treat. 2016;12:1837–1842. doi:. doi:10.2147/NDT.S97616 [CrossRef]
  3. Schizophrenia Research Institute. About Schizophrenia. http://www.schizophreniaresearch.org.au/schizophrenia/about-schizophrenia. Accessed February 13, 2019.
  4. The ICD-10 Classification of Mental and Behavioral Disorders. Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization; 1993.
  5. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
  6. Rethink Mental Illness. Schizophrenia. https://www.rethink.org/diagnosis-treatment/conditions/schizophrenia. Accessed February 13, 2019.
  7. Andreasen NC. Understanding the causes of schizophrenia. N Engl J Med. 1999; 340:645–647. doi:. doi:10.1056/NEJM199902253400811 [CrossRef]
  8. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–247. doi:10.1001/archpsyc.56.3.241 [CrossRef]
  9. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–2071. doi:. doi:10.1016/S0140-6736(12)60239-6 [CrossRef]
  10. Holder SD, Edmunds AL, Morgan S. Psychotic and bipolar disorders: antipsychotic drugs. FP Essent. 2017;455:23–29.
  11. Ayano G. First generation antipsychotics: pharmacokinetics, pharmacodynamics, therapeutic effects and side effects: a review. J Chemistry. 2016; 5:53–63.
  12. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005;20:15–27. doi:. doi:10.1016/j.eurpsy.2004.11.003 [CrossRef]
  13. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425. doi:. doi:10.1176/appi.ajp.161.3.414 [CrossRef]
  14. Ndukwe HC, Nishtala PS. Glucose monitoring in new users of second-generation antipsychotics in older people. Arch Gerontol Geriatr. 2017;70:136–140. doi:. doi:10.1016/j.archger.2017.01.006 [CrossRef]
  15. Sapra M, Lawson D, Iranmanesh A, Varma A. Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics. Schizophr Res. 2016;174:132–136. doi:. doi:10.1016/j.schres.2016.04.051 [CrossRef]
  16. Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017;6:397. doi:. doi:10.12688/f1000research.10233.1 [CrossRef]
  17. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21:123–127. doi:. doi:10.1017/S1092852916000043 [CrossRef]
  18. Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016; 10:327–338. doi:. doi:10.2147/DDDT.S95100 [CrossRef]
  19. Earley W, Durgam S, Lu K, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studies. J Affect Disord. 2017;215:205–212. doi:. doi:10.1016/j.jad.2017.03.032 [CrossRef]
  20. Ye N, Song Z, Zhang A. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-parkinsonian agents. Curr Med Chem. 2014;21:437–457. doi:10.2174/09298673113206660300 [CrossRef]
  21. Kehr J, Yoshitake T, Ichinose F, et al. Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity. Psychopharmacology (Berl). 2018;235:1593–1607. doi:. doi:10.1007/s00213-018-4874-z [CrossRef]
  22. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011;218:579–587. doi:. doi:10.1007/s00213-011-2343-z [CrossRef]
  23. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7:29–41. doi:. doi:10.1177/2045125316672136 [CrossRef]
  24. Wesolowska A, Partyka A, Jastrzebska-Wiesek M, Kolaczkowski M. The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opin Drug Discov. 2018;13:779–790. doi:. doi:10.1080/17460441.2018.1471057 [CrossRef]
  25. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328–340. doi:. doi:10.1124/jpet.109.160432 [CrossRef]
  26. Altinbas K, Guloksuz S, Oral ET. Clinical potential of cariprazine in the treatment of acute mania. Psychiatr Danub. 2013;25:207–213.
  27. Gao Y, Peterson S, Masri B, et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor beta-arrestin interactions. Pharmacol Res Perspect. 2015;3:e00073. doi:. doi:10.1002/prp2.73 [CrossRef]
  28. Choi YK, Adham N, Kiss B, Gyertyan I, Tarazi FI. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr. 2017;22:484–494. doi:. doi:10.1017/S1092852916000894 [CrossRef]
  29. Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016;165:164–177. doi:. doi:10.1016/j.pharmthera.2016.06.007 [CrossRef]
  30. Toth M, Varrone A, Steiger C, et al. Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates. Synapse. 2013;67:258–264. doi:. doi:10.1002/syn.21631 [CrossRef]
  31. Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925–935. doi:. doi:10.1016/j.neuint.2011.07.002 [CrossRef]
  32. Citrome L. Cariprazine for the treatment of schizophrenia: a review of this dopamine D3-preferring D3/D2 receptor partial agonist. Clin Schizophr Relat Psychoses. 2016;10:109–119. doi:. doi:10.3371/1935-1232-10.2.109 [CrossRef]
  33. European Medicines Agency E. Annex I: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002770/WC500234924.pdf. Accessed February 13, 2019.
  34. Campbell RH, Diduch M, Gardner KN, Thomas C. Review of cariprazine in management of psychiatric illness. Ment Health Clin. 2018;7:221–229. doi:. doi:10.9740/mhc.2017.09.221 [CrossRef]
  35. Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–328. doi:. doi:10.2147/TCRM.S35137 [CrossRef]
  36. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol. 2015;25:1882–1891. doi:. doi:10.1016/j.euroneuro.2015.08.020 [CrossRef]
  37. Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76:284–292. doi:. doi:10.4088/JCP.14m09081 [CrossRef]
  38. Earley W, Durgam S, Lu K, et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018;226:239–244. doi:. doi:10.1016/j.jad.2017.09.040 [CrossRef]
  39. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17:63–75. doi:. doi:10.1111/bdi.12238 [CrossRef]
  40. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011;216:451–473. doi:. doi:10.1007/s00213-011-2247-y [CrossRef]
  41. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11:802–812.
  42. Zimnisky R, Chang G, Gyertyan I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226:91–100. doi:. doi:10.1007/s00213-012-2896-5 [CrossRef]
  43. Watson DJG, King MV, Gyertyan I, Kiss B, Adham N, Fone KCF. The dopamine D(3)-preferring D(2)/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26:208–224. doi:. doi:10.1016/j.euroneuro.2015.12.020 [CrossRef]
  44. Garnock-Jones KP. Cariprazine: a review in schizophrenia. CNS Drugs. 2017;31:513–525. doi:. doi:10.1007/s40263-017-0442-z [CrossRef]
  45. Neill JC, Grayson B, Kiss B, Gyertyan I, Ferguson P, Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26:3–14. doi:. doi:10.1016/j.euroneuro.2015.11.016 [CrossRef]
  46. Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7)625–639. doi:. doi:10.1007/s00406-018-0869-3 [CrossRef]
  47. Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32:309–318. doi:. doi:10.1097/YIC.0000000000000189 [CrossRef]
  48. Zhao MJ, Qin B, Wang JB, et al. Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2018;38:55–59. doi:10.1097/JCP.0000000000000834 [CrossRef].
  49. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152:450–457. doi:. doi:10.1016/j.schres.2013.11.041 [CrossRef]
  50. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76:e1574–e1582. doi:. doi:10.4088/JCP.15m09997 [CrossRef]
  51. Nemeth B, Molnar A, Akehurst R, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6:639–648. doi:. doi:10.2217/cer-2017-0024 [CrossRef]
  52. Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyan I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567–574. doi:10.1097/FBP.0000000000000070 [CrossRef]
  53. Leggio GM, Salomone S, Bucolo C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013;719:25–33. doi:. doi:10.1016/j.ejphar.2013.07.022 [CrossRef]
  54. Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol. 2017;20:788–796. doi:. doi:10.1093/ijnp/pyx038 [CrossRef]
  55. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77:371–378. doi:. doi:10.4088/JCP.15m10070 [CrossRef]
  56. Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173:271–281. doi:. doi:10.1176/appi.ajp.2015.15020164 [CrossRef]
  57. Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016;77:109–115. doi:. doi:10.4088/JCP.15m10192 [CrossRef]
  58. Roman V, Gyertyan I, Saghy K, Kiss B, Szombathelyi Z. Cariprazine (RGH-188), a D(3)-preferring dopamine D(3)/D(2) receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology (Berl). 2013;226:285–293. doi:. doi:10.1007/s00213-012-2906-7 [CrossRef]
  59. Ketter TA, Sachs GS, Durgam S, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study. J Affect Disord. 2018;225:350–356. doi:. doi:10.1016/j.jad.2017.08.040 [CrossRef]
  60. Werner FM, Covenas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag. 2015;11:1657–1661. doi:10.2147/TCRM.S64915 [CrossRef].
  61. Nasrallah HA, Earley W, Cutler AJ, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17:305. doi:. doi:10.1186/s12888-017-1459-z [CrossRef]
  62. Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23:39–50. doi:. doi:10.1017/S1092852917000220 [CrossRef]
  63. Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int J Clin Psychopharmacol. 2016;31:61–68. doi:. doi:10.1097/YIC.0000000000000110 [CrossRef]
  64. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37:138–147. doi:. doi:10.1097/JCP.0000000000000665 [CrossRef]
  65. Fang F, Sun H, Wang Z, Ren M, Calabrese JR, Gao K. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016;30:845–867. doi:. doi:10.1007/s40263-016-0352-5 [CrossRef]
  66. Genaro-Mattos TC, Tallman KA, Allen LB, et al. Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. Toxicol Appl Pharmacol. 2018;349:21–28. doi:. doi:10.1016/j.taap.2018.04.029 [CrossRef]
  67. Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci. 2016;13:49–52.
  68. Girgis RR, Slifstein M, D'Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233:3503–3512. doi:. doi:10.1007/s00213-016-4382-y [CrossRef]
  69. Durgam S, Earley W, Lu K, et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis. Int J Clin Pract. 2017;71(12). doi:10.1111/ijcp.13037 [CrossRef]
  70. Romeo B, Blecha L, Locatelli K, Benyamina A, Martelli C. Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety. J Psychopharmacol. 2018;32:385–396. doi:. doi:10.1177/0269881118760661 [CrossRef]
  71. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170. doi:. doi:10.1111/bdi.12609 [CrossRef]
  72. Lao KS, He Y, Wong IC, Besag FM, Chan EW. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016;30:1043–1054. doi:. doi:10.1007/s40263-016-0382-z [CrossRef]
Authors

Ayman Antoun Reyad, PhD, PGCert, is a Senior Lecturer in Pharmacology, School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton. Raafat Mishriky, MBBCH, PgDip, MRCPsych, is a Consultant Old Age Psychiatrist, Birmingham and Solihull Mental Health National Health Service Foundation Trust; and an Honorary Senior Lecturer in Old Age Psychiatry, Aston Medical School, Aston University.

Address correspondence to Ayman Antoun Reyad, PhD, PGCert, MA Building, Wulfruna Street, School of Pharmacy, University of Wolverhampton, WV1 1LY, Wolverhampton, UK; email: a.antounreyad@wlv.ac.uk.

Disclosure: The authors have no relevant financial relationships to disclose.

10.3928/00485713-20190213-01

Sign up to receive

Journal E-contents